Streptomycin indications and usage: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 9: | Line 9: | ||
====Mycobacterium tuberculosis==== | ====Mycobacterium tuberculosis==== | ||
The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. | The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing [[isoniazid]] (INH), [[rifampin]] and [[pyrazinamide]] for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. | ||
Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. | Streptomycin is also indicated for therapy of [[tuberculosis]] when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. | ||
====Non-tuberculosis infections==== | ====Non-tuberculosis infections==== | ||
| Line 17: | Line 17: | ||
The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. | The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. | ||
* Pasteurella pestis (plague) | * [[Pasteurella pestis]] (plague) | ||
* Francisella tularensis (tularemia) | |||
* Brucella | * [[Francisella tularensis]] (tularemia) | ||
* Calymmatobacterium granulomatis (donovanosis, granuloma inguinale) | |||
* H. ducreyi (chancroid) | * [[Brucella]] | ||
* H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent) | |||
* K. pneumoniae pneumonia (concomitantly with another antibacterial agent) | * [[Calymmatobacterium granulomatis]] (donovanosis, granuloma inguinale) | ||
* E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections | |||
* Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin) | * [[H. ducreyi]] (chancroid) | ||
* Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent) | |||
* [[H. influenzae]] (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent) | |||
* [[K. pneumoniae]] pneumonia (concomitantly with another antibacterial agent) | |||
* [[E. coli]], [[Proteus]], [[A. aerogenes]], [[K. pneumoniae]], and [[Enterococcus faecalis]] in urinary tract infections | |||
* [[Streptococcus viridans]], [[Enterococcus faecalis]] (in endocardial infections - concomitantly with penicillin) | |||
* [[Gram-negative]] bacillary [[bacteremia]] (concomitantly with another antibacterial agent) | |||
To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STREPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e | publisher = | date = | accessdate = }}</ref> | To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = STREPTOMYCIN INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [X-GEN PHARMACEUTICALS, INC.] | url =http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=abd1f64e-4283-4370-aae8-3666316aa36e | publisher = | date = | accessdate = }}</ref> | ||
Revision as of 18:00, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Indications and Usage
Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below:
Mycobacterium tuberculosis
The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered.
Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings.
Non-tuberculosis infections
The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents.
- Pasteurella pestis (plague)
- Francisella tularensis (tularemia)
- Calymmatobacterium granulomatis (donovanosis, granuloma inguinale)
- H. ducreyi (chancroid)
- H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent)
- K. pneumoniae pneumonia (concomitantly with another antibacterial agent)
- E. coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections
- Streptococcus viridans, Enterococcus faecalis (in endocardial infections - concomitantly with penicillin)
- Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent)
To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.[1]
References
Adapted from the FDA Package Insert.